VOLGA

1. 02:15
   x.com

   Is Less Enough and More Too Much? Implications of #VOLGA for the Peri-Operative Therapeutic Landscape in MIBC. Presented by @MichvdHeijden @NKI_nl. #ESMO26 written coverage by @cha
2. 00:42
   x.com

   The interim analysis of the phase 3 VOLGA study found improved EFS for patients with MIBC when treated with neoadjuvant durvalumab & enfortumab vedotin.

1. 23:23
   x.com

   *VOLGA study* cis-ineligible/refused @tompowles1 @MichvdHeijden @myESMO #ESMO26 @oncodaily @OncoAlert
2. 22:45
   x.com

   Perioperative Durvalumab ± Tremelimumab + Neoadjuvant EV in MIBC: Phase 3 VOLGA Trial. Presented by @tompowles1 @QMBCI. #ESMO26 written coverage by @chavarriagaj @PSH_Urology >
3. 22:15
   x.com

   #ESMO26|#VOLGA
4. 22:00
   x.com

   Original Article: Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer (phase 3 VOLGA trial) https://nej.md/4z7dQFm
5. 20:31
   x.com

   👥 Consenso de los KOLs en #ESMO26 ¿quién apoya cada ensayo?
6. 20:17
   x.com

   VOLGA delivers meaningful survival benefit.
7. 20:00
   x.com

   🚨 Positive results from the phase 3 VOLGA trial presented at #ESMO26
8. 18:31
   x.com

   #ESMO26 VOLGA (phase III, N=695): MIBC patients ineligible for or declining cisplatin. Perioperative durvalumab + neoadjuvant enfortumab vedotin vs radical cystectomy ± adjuvant th
9. 14:37
   x.com

   My take on VOLGA at #ESMO26:
10. 13:55
    x.com

    The #OncoAlertTopTweet Day2 of #ESMO26
11. 12:49
    x.com

    Five absolute signals after PS I #ESMO26
12. 11:52
    x.com
13. 08:08
    x.com

    #ESMO26 #GU #UC #MIBC
14. 07:06
    x.com

    Inspiring to be at the first presidential session of #ESMO26 with two P3 trials pushing the boundaries of perioperative cancer treatment in very different ways.
15. 03:09
    x.com

    🚨⭐ #ESMO26 | GU ONCOLOGY — DAY 2 HIGHLIGHTS
16. 03:00
    x.com

    #ESMO26 | Abstract #LBA2 | VOLGA | Presented by @tompowles1 | @OncoAlert
17. 02:15
    x.com

    💥 Survival was improved with durvalumab plus enfortumab vedotin in patients with MIBC according to new data from the phase 3 VOLGA trial
18. 02:05
    x.com

    Congratulations @tompowles1 and team! EVD #VOLGA #ESMO26
19. 01:58
    x.com

    📌 An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
20. 01:57
    x.com

    #ESMO26 Very thoughtful and balanced discussion of VOLGA trial by @MichvdHeijden , putting EV-D in perspective with EV-303/B15 on efficacy & safety.
21. 01:41
    x.com

    🚨⭐ #ESMO26 | GU ONCOLOGY — DAY 2 HIGHLIGHTS
22. 01:26
    x.com

    VOLGA at #ESMO2026: Perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved EFS and OS in patients with MIBC ineligible for or refusing cisplatin. @tomp
23. 01:23
    x.com

    A new SoC in cisplatin ineligible muscle-invasive bladder cancer: The VOLGA Trial. Neoadjuvant Durva plus EV, without adjuvant EV. Less is more. #BladderCancer #ESMO26 @myESMO @sog
24. 01:21
    x.com

    #ScienceLink #Madrid2026 #ESMO26 #VOLGA #Durvalumab
25. 00:59
    x.com

    🚨⭐🟠 #ESMO26 | Presidential Symposium | LBA2 | VOLGA
26. 00:55
    x.com

    Kudos @tompowles1 on a fantastic #VOLGA presidential @ #ESMO26 👏
27. 00:42
    x.com

    🎯 #ESMO2026 | VOLGA: pueden cambiar la práctica clínica en cáncer de vejiga músculo-invasivo.
28. 00:17
    x.com

    Day 2 (Presidential) #ESMO26
29. 00:12
    x.com

    VOLGA tested for the 1st time a triplet with ADC + dual checkpoint inhibition in the neoadjuvant setting for cis-ineligible MIBC #ESMO26
30. 00:09
    x.com

    As presented at #ESMO2026, perioperative #durvalumab plus neoadjuvant enfortumab vedotin significantly improved survival in patients with muscle-invasive bladder cancer who were in
31. 00:01
    x.com

    Important data by Dr. Bedke & @AndreaNecchi in localized MIBC: periop addition of anti-PD1 not better vs neoadjuvant Gem/Cis alone; discordant with NIAGARA data. Periop EV/ICI
32. 00:01
    x.com

    #ESMO26: i risultati dello studio VOLGA aprono nuove prospettive nella cura del #tumoredellavescica muscolo-invasivo.

1. 23:59
   x.com

   Resultados de VOLGA presentados en #ESMO26 @tompowles1
2. 23:47
   x.com

   #ESMO26 Dr. Michiel van der Heijden discussed the implications of VOLGA alongside KEYNOTE-905 and KEYNOTE-B15:
3. 23:46
   x.com

   Fantastic presentation by @tompowles1 @Uromigos on VOLGA trial showing practice changing EFS/OS benefit with neoadjuvant EV/durva ->RC ->durva vs no peri-op Tx in cisplatin-u
4. 23:43
   x.com

   #ESMO26 VOLGA: Could just 3 cycles of neoadjuvant EV redefine treatment for cisplatin-ineligible MIBC?
5. 23:42
   x.com

   👑 This is why #Podium2Screen works!
6. 23:37
   x.com

   #ESMO26 | VOLGA in cisplatin-ineligible MIBC: Durvalumab + enfortumab vedotin significantly improved: OS: HR 0.58 (p=0.0027) EFS: HR 0.51 (p<0.0001) 2-year OS: 78% vs 69%ctDNA c
7. 23:33
   x.com

   Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial
8. 23:32
   x.com

   VOLGA trial : The Arm1 - in MIBC, neoadjuvant Durvalumab + EV followed by surgery then adjuvant Durvalumab showed better EFS (NR vs 12 months HR 0.51) and OS (NR in both arms, HR 0
9. 23:31
   x.com

   🔊👏Bravo Dr Thomas Powles @TomPowles1 Outstanding Presentation @ Presidential Symposium, Topline Results VOLGA Trial, Perioperative durvalumab w/ or without tremelimumab + neoadj en
10. 23:30
    x.com

    VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61).
11. 23:29
    x.com

    @tompowles1 presented VOLGA at #ESMO26: perioperative durvalumab + neoadjuvant EV vs control in cisplatin-ineligible MIBC
12. 23:29
    x.com

    An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session
13. 23:26
    x.com

    An important practical question from VOLGA:
14. 23:26
    x.com

    Volga EFS and OS for Durva/EV and Durva/Treme #ESMO26 #oncoalert
15. 23:26
    x.com

    @tompowles1 with #VOLGA phase 3 of EV-durva, EV-tremi-durva, vs cystectomy. EV-durva improved EFS & OS. Great to see survival improved w neoadj doublet. Triplet misses partly d
16. 23:26
    x.com

    A fascinating VOLGA finding:
17. 23:25
    x.com

    Strong VOLGA Phase III results at #ESMO26!
18. 23:24
    x.com

    #ESMO26 🔬 VOLGA (Phase 3) Peri-op durvalumab ± tremelimumab + neoadjuvant EV ×3 vs upfront cystectomy in cisplatin-ineligible MIBC
19. 23:24
    x.com

    #ESMO26 @tompowles1 presents at the 👑presidential 👑 session VOLGA n=1009 phIII neoadjuvant #bladdercancer trial. 24mo EFS 63.5% vs 45% (HR 0.51), pCR 45% vs 10%. Triplet +tremelimu
20. 23:23
    x.com

    Looking for context to interpret VOLGA at #ESMO26 after the presentation in the presidential session?
21. 23:22
    x.com

    These are THE curves. Volga . New SOC .@tompowles1 @myESMO #ESMO26 @OncoAlert @OncBrothers . 3 dose of Pre operative EV are enough.
22. 23:21
    x.com

    VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy a
23. 23:20
    x.com

    🇬🇧 Brilliant to see @tompowles1 AGAIN on the podium, leading the way in bladder cancer!
24. 23:20
    x.com

    🔥 Presidential Symposium I #ESMO26
25. 23:19
    x.com

    VOLGA: perioperative EV + Durvalumab increases pCR, EFS and OS compared with cystectomy alone. A new standard option for these patients, in a setting that is becoming really crowde
26. 23:19
    x.com

    VOLGA shows Improved EFS and OS for Durva/EV presented by @tompowles1 #ESMO26 #oncoalert
27. 23:18
    x.com

    Excellent presentation by @tompowles1! VOLGA: perioperative durvalumab + 3 cycles of neoadjuvant EV improved EFS (HR 0.51) and OS (HR 0.58) vs cystectomy ± adjuvant therapy in cisp
28. 23:17
    x.com

    #ESMO26 | VOLGA
29. 23:16
    x.com

    Presidential symposium 1️⃣!!
30. 23:15
    x.com

    VOLGA: OS benefit without adjuvant EV.
31. 23:00
    x.com

    #ESMO26: Neoadjuvant enfortumab vedotin significantly improved event-free and overall survival when added to peri-operative durvalumab for muscle-invasive #BladderCancer (#MIBC) in
32. 22:41
    x.com

    #ESMO26 NEJM
33. 22:36
    x.com

    The #ESMO26 Presidential Symposium is about to begin! 🔥
34. 22:35
    x.com

    Presented at #ESMO26:
35. 22:27
    x.com

    🔥 full house before #ESMO26 Presidential:
36. 20:53
    x.com

    🔥 #ESMO2026 late-breakers 24 Oct scored 1–10 for SoC impact
37. 20:45
    x.com

    OncoAlert 4Sight Abstracts to be Presented at #ESMO26
38. 19:10
    x.com

    🚨 #IUCS Clinical Poll | #ESMO26
39. 14:50
    x.com

    With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.
40. 14:09
    x.com

    VOLGA (LBA2, #ESMO26): cisplatin-ineligible/refusing MIBC — neoadjuvant enfortumab vedotin + peri-op durvalumab vs control.
41. 13:45
    x.com

    An important survival result in muscle-invasive bladder cancer from #ESMO26 📊
42. 11:26
    x.com

    IO + EV upfront is now the SoC for MIBC!! But how much EV do we need in postOP settings? Eagerly looking forward to more data/discussion on Day 2 #ESMO26! VOLGA as the new SoC!!??!
43. 10:30
    nejm.org

    Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
44. 06:52
    x.com

    #ESMO26 | VOLGA | Presidential Symposium-1

1. 20:06
   x.com

   Excellent presentation by Jens presenting results from KN866 trial that did not meet its primary endpoint in contrast with NIAGARA. Peri-op EV-pembro is the SOC in MIBC, awaiting V
2. 19:46
   x.com

   Full house for Bladder/RCC updates first with #KN866 #ESMO26
3. 17:25
   x.com

   🚨 #ESMO26 GU Oncology — the studies I would keep closest on the radar
4. 16:37
   x.com

   Lovely walking tour & sunset in Madrid @myESMO #ESMO26
5. 07:19
   x.com

   ✈️ En route to Madrid for #ESMO26, landing just in time for the data to start Friday morning. Most excited for: VOLGA LBA2 in bladder cancer, INTerpath-001's first phase 3 neoantig
6. 04:15
   x.com

   🔬 GU cancer data to watch at #ESMO26:

1. 03:05
   x.com

   The ten trials oncologists are waiting for at #ESMO26, ranked by how many physicians posted about each one before Madrid. Top three: VOLGA, INTerpath-001, DeLLphi-305. Flagged by @…

1. 17:30
   x.com

   🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯 #BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866 #ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS #KidneyCancer: LITE…

1. 22:15
   x.com

   2/4 #BladderCancer at #ESMO26 🟢 #VOLGA — LBA2 - Positive EFS/OS topline announced for durva + EV. Looking for the magnitude of benefit, surgical outcomes, and toxicity. - We know …
2. 08:02
   x.com

   #ESMO26 is nearly here, and I'm hyped. Ten of 12 Presidential abstracts are expected to show primary endpoints met. Seven have declared a survival win, including the VOLGA trial no…

Heat now 287·Peak in the comparable set 383 (Oct 25 04:00)·Change over 24h in the comparable set -20%·Participants now 60

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.